1 |
Stone MJ. Monoclonal antibodies in the prehybridoma era: a brief historical perspective and personal reminiscence. Clin Lymphoma 2001;2:148-54
DOI
ScienceOn
|
2 |
Buske C, Dreyling M. Unterhalt MHiddemann W [Monoclonal antibody therapy for malignant lymphoma]. Med Klin (Munich) 2005;100:14-24
DOI
|
3 |
Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 2001;39:195-201
DOI
ScienceOn
|
4 |
van Laarhoven HW, Punt CJ. Systemic treatment of advanced colorectal carcinoma. Eur J Gastroenterol Hepatol 2004;16:283-9
|
5 |
Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57
DOI
ScienceOn
|
6 |
Cilley J, Winter JN. Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas. Haematologica 2006;91:113-20
|
7 |
DeNardo GL, Kukis DL, Shen S, DeNardo DA, Meares CFDe, Nardo SJ. Cu-versus I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res 1999;5:533-41
|
8 |
Choi CW, Lang L, Lee JT, Webber KO, Yoo TM, Chang HK, et al. Biodistribution of F- and I-labeled anti-Tac disulfide- stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts. Cancer Res 1995;55:5323-9
|
9 |
Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 1997;44:179-88
DOI
|
10 |
Blend MJ, Greager JA, Atcher RW, Brown JM, Brechbiel MW, Gansow OA, et al. Improved sarcoma imaging and reduced hepatic activity with indium-111-SCN-Bz-DTPA linked to MoAb 19-24. J Nucl Med 1988;29:1810-6
|
11 |
DeNardo GL, DeNardo SJ, O'Donnell RT, Kroger LA, Kukis DL, Meares CF, et al. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1antibody in patients with non-Hodgkin's lymphoma. Clin Lymphoma 2000;1:118-26
DOI
ScienceOn
|
12 |
Visser GW, Gerretsen M, Herscheid JD, Snow GBvan, Dongen G. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med 1993;34:1953-63
|
13 |
Weadock KS, Sharkey RM, Varga DC, Goldenberg DM. Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 1990;31:508-11
|
14 |
Behr TM, Gotthardt M, Becker W, Behe M. Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy. A review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Gottingen/Marburg experience. Nuklearmedizin 2002;41:71-9
DOI
|
15 |
Griffiths GL, Goldenberg DM, Knapp FF, Jr., Callahan AP, Chang CH, Hansen HJ. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies. Cancer Res 1991;51:4594-602
|
16 |
John E, Thakur ML, DeFulvio J, McDevitt MR, Damjanov I. Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: preparation and evaluation. J Nucl Med 1993;34:260-7
|
17 |
Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR. Preclinical evaluation of Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 1999;15:1017-25
|
18 |
DeNardo GL, Mirick GR, Kroger LA, Bradt BM, Lamborn KR, DeNardo SJ. Characterization of human IgG antimouse antibody in patients with B-cell malignancies. Clin Cancer Res 2003;9:4013S-21S
|
19 |
Illidge TM, Brock S. Radioimmunotherapy of cancer: using monoclonal antibodies to target radiotherapy. Curr Pharm Des 2000;6:1399-418
DOI
|
20 |
Lewis MR, Zhang J, Jia F, Owen NK, Cutler CS, Embree MF, et al. Biological comparison of Pm-, Ho-, and Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft- bearing nude mice. Nucl Med Biol 2004;31: 213-23
DOI
ScienceOn
|
21 |
Najafi A, Alauddin MM, Sosa A, Ma GQ, Chen DC, Epstein AL, et al. The evaluation of Re-labeled antibodies using N2S4 chelate in vitro and in vivo using tumor-bearing nude mice. Int J Rad Appl Instrum B 1992;19:205-12
DOI
ScienceOn
|
22 |
Boucek JA, Turner JH. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2005;32:458-69
DOI
|
23 |
Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 2005;54: 11-29
DOI
ScienceOn
|
24 |
Kraeber-Bodere F, Mishra A, Thedrez P, Faivre-Chauvet A, Bardies M, Imai S, et al. Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer. Eur J Nucl Med 1996;23:560-7
DOI
ScienceOn
|
25 |
Macklis RM, Kaplan WD, Ferrara JL, Kinsey BM, Kassis AIBurakoff SJ Biodistribution studies of anti-Thy 1.2 IgM immunoconjugates: implications for radioimmunotherapy. Int J Radiat Oncol Biol Phys 1988;15:383-9
DOI
ScienceOn
|
26 |
Izard ME, Boniface GR, Hardiman KL, Brechbiel MW, Gansow OA, Walkers KZ. An improved method for labeling monoclonal antibodies with samarium-153: use of the bifunctional chelate 2-(p-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid. Bioconjug Chem 1992;3:346-50
DOI
|
27 |
Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995;28:126-42
DOI
ScienceOn
|
28 |
Lee YC, Washburn LC, Sun TT, Byrd BL, Crook JE, Holloway EC, et al. Radioimmunotherapy of human colorectal carcinoma xenografts using Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques. Cancer Res 1990;50:4546-51
|
29 |
Kobayashi H, Kao CH, Kreitman RJ, Le N, Kim MK, Brechbiel MW, et al. Pharmacokinetics of In- and I-labeled antiTac single-chain Fv recombinant immunotoxin. J Nucl Med 2000;41:755-62
|
30 |
Gregory SA. Selecting patients for treatment with Y ibritumomab tiuxetan (Zevalin). Semin Oncol 2003;30:17-22
|
31 |
Davies AJ. A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma. Expert Opin Biol Ther 2005;5:577-88
DOI
ScienceOn
|
32 |
Buchsbaum DJ, Lawrence TS. New trends in the use of radioimmunoconjugates for the therapy of cancer. Targeted Diagn Ther 1990;3:215-55
|
33 |
Yoo TM, Chang HK, Choi CW, Webber KO, Le N, Kim IS, et al. Technetium-99m labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment. J Nucl Med 1997;38:294-300
|
34 |
Fink-Bennett DM, Thomas K. Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. J Nucl Med Technol 2003;31:61-8; quiz 69-70
|
35 |
Illidge TM, Johnson PW. The emerging role of radioimmunotherapy in haematological malignancies. Br J Haematol 2000;108:679-88
DOI
ScienceOn
|
36 |
DeNardo GL, O'Donnell RT, Shen S, Kroger LA, Yuan A, Meares CF, et al. Radiation dosimetry for Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J Nucl Med 2000;41:952-8
|
37 |
Behr TM, Behe M, Lohr M, Sgouros G, Angerstein C, Wehrmann E, et al. Therapeutic advantages of Auger electron- over beta- emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med 2000;27:753-65
DOI
|
38 |
Anderson WT, Strand M. Radiolabeled antibody: iodine versus radiometal chelates. NCI Monogr 1987;149-51
|
39 |
Friedberg JW, Fisher RI. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 2004;4:18-26
DOI
ScienceOn
|
40 |
Nishihara T, Sawada T, Yamamoto A, Yamashita Y, Ho JJ, Kim YS, et al. Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for pancreatic cancer. Jpn J Cancer Res 2000;91:817-24
DOI
|
41 |
Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, et al. Biodistribution and therapeutic efficacy of I-, Re-, Y-, or Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med 2004;45: 1224-32
|
42 |
Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm 2003;18:513-24
DOI
ScienceOn
|
43 |
Lewington V. Development of I-tositumomab. Semin Oncol 2005;32:S50-6
|
44 |
Hamby CV, Chinol M, Manzo C, Ferrone S. Purification by affinity chromatography with anti-idiotypic monoclonal antibodies of immunoreactive monoclonal antibodies following labeling with Re. Hybridoma 1997;16:27-31
DOI
ScienceOn
|
45 |
Stimmel JB, Kull FC, Jr. Samarium-153 and lutetium-177 chelation properties of selected macrocyclic and acyclic ligands. Nucl Med Biol 1998;25:117-25
DOI
ScienceOn
|
46 |
Press OW, Rasey J. Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol 2000;27:62-73
|
47 |
Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, et al. Phase I/II Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000;27:766-77
DOI
|
48 |
Fani M, Xanthopoulos S, Archimandritis SC, Stratis N, Bouziotis P, Loudos G, et al. Biodistribution and scintigraphic studies of Sm-labeled anti-CEA monoclonal antibody for radioimmunoscintigraphy and radioimmunotherapy. Anticancer Res 2003;23:2195-9
|
49 |
Crudo JL, Edreira MM, Obenaus ER, Chinol M, Paganelli Gde Castiglia SG Optimization of antibody labeling with rhenium-188 using a prelabeled MAG3 chelate. Int J Pharm 2002;248:173-82
DOI
ScienceOn
|
50 |
van Gog FB, Visser GW, Stroomer JW, Roos JC, Snow GBvan, Dongen GA. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions. Cancer 1997;80:2360-70
DOI
ScienceOn
|
51 |
Mirick GR, Bradt BM, Denardo SJ, Denardo GL. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging 2004;48:251-7
|
52 |
Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004;5:292-302
DOI
ScienceOn
|
53 |
Scheidhauer K, Wolf I, Baumgartl HJ, Von Schilling C, Schmidt B, Reidel G, et al. Biodistribution and kinetics of I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2002;29:1276-82
DOI
ScienceOn
|
54 |
Wurflein D, Dechant M, Stockmeyer B, Tutt AL, Hu P, Repp R, et al. Evaluating antibodies for their capacity to induce cell- mediated lysis of malignant B cells. Cancer Res 1998;58:3051-8
|
55 |
Behr TM, Sgouros G, Vougiokas V, Memtsoudis S, Gratz S, Schmidberger H, et al. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of I- vs. I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer 1998;76:738-48
DOI
ScienceOn
|
56 |
Fani M, Vranjes S, Archimandritis SC, Potamianos S, Xanthopoulos S, Bouziotis P, et al. Labeling of monoclonal antibodies with Sm for potential use in radioimmunotherapy. Appl Radiat Isot 2002;57:665-74
DOI
ScienceOn
|
57 |
Juweid ME, Sharkey RM, Behr T, Swayne LC, Dunn R, Siegel J, et al. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2. J Nucl Med 1996;37:1504-10
|
58 |
DeNardo GL, Raventos A, Hines HH, Scheibe PO, Macey DJ, Hays MT, et al. Requirements for a treatment planning system for radioimmunotherapy. Int J Radiat Oncol Biol Phys 1985;11:335-48
DOI
ScienceOn
|
59 |
Behr TM, Griesinger F, Riggert J, Gratz S, Behe M, Kaufmann CC, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002;94:1363-72
DOI
ScienceOn
|